{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:50Z","timestamp":1787071070822,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We report the long term follow-up, toxicity, and outcomes of patients with localized squamous cell carcinoma of the esophagus(ESCC) who underwent definitive chemo-radiotherapy(dCRT) at our institute.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients diagnosed with carcinoma post cricoid, upper cervical and thoracic oesophagus and treated with dCRT between January 2000 and March 2012 were retrospectively analyzed. Radiotherapy was delivered in two phases to a maximum dose of 63Gy in daily fractions of 1.8Gy using conventional or conformal techniques. OS and PFS were defined from date of registration and were calculated by Kaplan-Meier method with comparisons between different subgroups performed using log-rank test. All data were analysed using SPSS Version 22.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three hundred and fourteen patients with ESCC treated with dCRT were included in this analysis. Median age at presentation was 56 years and median KPS at presentation was 70. Two-third of patients were treated with conformal technique. Median dose of radiation delivered was 60Gy(range 30.6Gy\u201370Gy). Neoadjuvant chemotherapy was administered in about 35% patients and 57% patients received concurrent chemotherapy. About 10% patients required hospitalization during treatment due to complications and 7 patients did not complete treatment. Grade 1\/2 dermatitis and mucositis was seen in 77% and 71% patients respectively. Complete response at first follow up was observed in 56% of patients. At a median follow up of 56 months, 77 patients were alive with controlled disease. The 1- and 3-yr OS were 80% and 62% respectively. Median PFS was 28 months; 1- and 3-yr PFS were 66% and 46% respectively. A higher RT dose was found to be a significant predictor for OS and PFS on both uni- and multivariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study highlights that the delivery of higher RT doses (\u226563Gy) is feasible in this patient group and that a higher RT dose was associated with significantly better PFS and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_404_20","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:05:12Z","timestamp":1671156312000},"page":"S285-S292","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Definitive radiation therapy with dose escalation is beneficial for patients with squamous cell cancer of the esophagus"],"prefix":"10.4103","volume":"18","author":[{"given":"Sarbani","family":"Ghosh-Laskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Mummudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Chandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Tibdewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Praklash","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabita","family":"Jiwnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Karimundackal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Pramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-25-20241021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CMAR.S144687","article-title":"Radiotherapy for esophageal carcinoma: Dose, response and survival","volume":"10","author":"Luo","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R3-25-20241021","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"key":"R4-25-20241021","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41467-017-01730-x","article-title":"Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations","volume":"8","author":"Deng","year":"2017","journal-title":"Nat Commun"},{"key":"R5-25-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-31302-y","article-title":"Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer","volume":"8","author":"Fan","year":"2018","journal-title":"Sci Rep"},{"key":"R6-25-20241021","doi-asserted-by":"crossref","first-page":"e7685","DOI":"10.1097\/MD.0000000000007685","article-title":"Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine (Baltimore"},{"key":"R7-25-20241021","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-25-20241021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3727\/096504016X14537290676865","article-title":"Clinical outcome in definitive concurrent chemoradiation with weekly paclitaxel and carboplatin for locally advanced esophageal and junctional cancer","volume":"23","author":"Noronha","year":"2016","journal-title":"Oncol Res"},{"key":"R11-25-20241021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1634\/theoncologist.9-2-147","article-title":"Multiple management modalities in esophageal cancer: Combined modality management approaches","volume":"9","author":"Koshy","year":"2004","journal-title":"Oncologist"},{"key":"R12-25-20241021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1245\/ASO.2006.08.022","article-title":"Should resectable esophageal cancer be resected?","volume":"13","author":"Mariette","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R13-25-20241021","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(07)70172-9","article-title":"Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities","volume":"8","author":"Mariette","year":"2007","journal-title":"Lancet Oncol"},{"key":"R14-25-20241021","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ijrobp.2008.08.046","article-title":"Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort","volume":"74","author":"Smith","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-25-20241021","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"R16-25-20241021","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A Phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-25-20241021","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","article-title":"Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus","volume":"23","author":"Stahl","year":"2005","journal-title":"J Clin Oncol"},{"key":"R18-25-20241021","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-25-20241021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12957-018-1470-y","article-title":"The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma","volume":"16","author":"Ma","year":"2018","journal-title":"World J Surg Oncol"},{"key":"R20-25-20241021","doi-asserted-by":"crossref","first-page":"S625","DOI":"10.21037\/tcr.2017.05.26","article-title":"Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma","volume":"6","author":"Post","year":"2017","journal-title":"Transl Cancer Res"},{"key":"R21-25-20241021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): A prospective multicentre, diagnostic cohort study","volume":"19","author":"Noordman","year":"2018","journal-title":"Lancet Oncol"},{"key":"R22-25-20241021","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ijrobp.2016.08.016","article-title":"Radiation dose escalation in esophageal cancer revisited: A contemporary analysis of the national cancer data base, 2004 to 2012","volume":"96","author":"Brower","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-25-20241021","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.radonc.2016.04.042","article-title":"Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis","volume":"120","author":"Chen","year":"2016","journal-title":"Radiother Oncol"},{"key":"R24-25-20241021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.radonc.2017.08.025","article-title":"Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma","volume":"125","author":"Chang","year":"2017","journal-title":"Radiother Oncol"},{"key":"R25-25-20241021","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1586\/14737140.2015.1074041","article-title":"High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and pooled analysis","volume":"15","author":"Song","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"R27-25-20241021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/028418602320405050","article-title":"Safety and efficacy of concurrent cisplatin and radiotherapy in inoperable or metastatic squamous cell esophageal cancer","volume":"41","author":"Kumar","year":"2002","journal-title":"Acta Oncol"},{"key":"R28-25-20241021","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10147-018-1240-4","article-title":"A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma","volume":"23","author":"Xia","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"R29-25-20241021","doi-asserted-by":"crossref","first-page":"e10928","DOI":"10.1097\/MD.0000000000010928","article-title":"Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore"},{"key":"R30-25-20241021","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1245\/s10434-008-0084-y","article-title":"Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response","volume":"15","author":"Barbour","year":"2008","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_404_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:04Z","timestamp":1787067664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_404_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_404_20","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.29.20077826","asserted-by":"object"}]},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}